Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 3/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599586 | 0.84 | TSHR (0.36) | BRD4CREBBPHTR1ADRD2DRD3 | |
| SCHEMBL3594039 | 0.84 | DDB1 (0.33) | HTR1ADRD2DRD3DDB1CRBN | |
| SCHEMBL3597334 | 0.83 | DDB1 (0.35) | HTR1ADRD2DRD3DDB1CRBN | |
| SCHEMBL3593970 | 0.83 | TRPV1 (0.38) | DRD2DRD3DDB1CRBN | |
| SCHEMBL3596677 | 0.82 | CRBN (0.33) | BRD4CREBBPHTR1ADRD2DRD3 | |
| SCHEMBL3594028 | 0.81 | TRPV1 (0.40) | DDB1CRBN | |
| SCHEMBL7341940 | 0.78 | ALOX5 (0.40) | DRD2DDB1CRBN | |
| SCHEMBL3593976 | 0.77 | CREBBP (0.34) | BRD4CREBBPHTR1ADRD2DRD3 | |
| SCHEMBL3606126 | 0.73 | CREBBP (0.32) | BRD4CREBBP | |
| SCHEMBL3593849 | 0.71 | DRD2 (0.41) | HTR1ADRD2CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | BRD4 706/4885CREBBP 2015/4885HTR1A 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.